Skip to content
PeptideNot WADA ProhibitedCompare

Setmelanotide

Also known as: Imcivree, RM-493, Setmelanotide acetate

2
1 · Natty510 · Enhanced

Lower numbers = closer to natural. Higher numbers = more enhanced.

Why this rating?

Setmelanotide is a selective melanocortin-4 receptor (MC4R) agonist and an FDA-approved prescription drug (Imcivree) for chronic weight management in rare genetic obesity - it activates MC4R in the hypothalamus to reduce appetite and increase resting energy expenditure (without raising heart rate or blood pressure). It is not an anabolic or androgenic drug and has no muscle-building effect; its use is targeted therapy for specific genetic and acquired obesity conditions. Rated 2 (not 1) because it is a genuine appetite-suppressing, energy-expenditure-raising metabolic drug that produces real body-composition change via fat loss - a real, if narrow and modestly-dosed, indirect enhancement path distinct from purely cosmetic or restorative peptides.

Overview

A selective agonist of the melanocortin-4 receptor (MC4R), marketed as Imcivree. It was approved by the FDA in November 2020 as a first-in-class treatment for chronic weight management in patients aged 6 and older with obesity due to genetically confirmed pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency, and was later approved (FDA 2022, EMA 2021) for weight management in Bardet-Biedl syndrome (BBS). In March 2026 the FDA further approved it for acquired hypothalamic obesity (age 4+) - hypothalamic damage, most often from a brain tumor or its treatment, that disrupts the same MC4R pathway - which unlike the other indications does not require genetic testing. It remains not approved for common/general (polygenic) obesity.

Important Warnings

  • •Depression and suicidal ideation are a listed Warning and Precaution, not a rare event (depression ~26% and suicidal ideation ~11% in the open-label POMC/PCSK1/LEPR studies, per the FDA label) - discontinue and seek care for new or worsening depression or suicidal thoughts.
  • •Genetic testing is required to confirm POMC, PCSK1 or LEPR deficiency before starting therapy for that indication - it is not approved for common/general (polygenic) obesity.
  • •The FDA label also notes hypersensitivity reactions and, in acquired-hypothalamic-obesity patients, risk of acute adrenal insufficiency and sodium/fluid imbalance - use requires ongoing physician supervision.
  • •Not recommended for use in end-stage renal disease; dose reduction is required for severe renal impairment (per the FDA label).

Purpose & Use Cases

Genetic Obesity (POMC / PCSK1 / LEPR deficiency)

Its original FDA indication - chronic weight management in patients 6+ with obesity from these confirmed pathogenic variants, which impair the leptin-melanocortin pathway upstream of MC4R.

Bardet-Biedl Syndrome (BBS)

Approved (FDA 2022, EMA 2021) for weight management and control of hunger in genetically confirmed BBS, another disorder affecting the same hypothalamic pathway.

Appetite / Energy-Expenditure Modulation

Mechanistically it reduces appetite and raises resting energy expenditure via central MC4R activation, without raising heart rate or blood pressure.

Acquired Hypothalamic Obesity (HO)

Approved by the FDA in March 2026 for patients 4+ whose hypothalamus was damaged (typically by a brain tumor, its surgery, or radiation), disrupting the same MC4R appetite pathway. This indication does not require genetic testing.

Benefits

  • FDA-approved, mechanism-targeted therapy for specific rare genetic obesities and acquired hypothalamic obesity
  • Reduces appetite and increases resting energy expenditure via central MC4R activation
  • Does not raise heart rate or blood pressure (unlike many stimulant appetite drugs)
  • Not androgenic or anabolic - no HPTA effect, no PCT

Good to Know

A real FDA-approved drug - for rare genetic obesity, not the gym

Setmelanotide (Imcivree) is an MC4R agonist approved by the FDA in November 2020 for obesity from POMC, PCSK1 or LEPR deficiency, and in 2022 for Bardet-Biedl syndrome. It requires genetic confirmation and is not approved for common obesity - it corrects a specific broken step in the hypothalamic hunger pathway.

MC4R = appetite and energy expenditure

It activates MC4 receptors in the hypothalamus (the paraventricular nucleus and lateral hypothalamic area), reducing appetite and increasing resting energy expenditure - and notably without raising heart rate or blood pressure, unlike stimulant-type appetite suppressants.

Melanocortin side effects come with the mechanism

Because it hits the melanocortin system, expected effects include skin hyperpigmentation and, less commonly, spontaneous erections / sexual reactions - the same receptor family responsible for the melanotans' pigment and libido effects. Depression and suicidal ideation have also been reported and warrant monitoring.

Not anabolic, not androgenic

It does nothing for muscle, strength or testosterone and does not touch the HPTA, so no PCT is involved. Its relevance is metabolic/appetite, and specifically for rare genetic and acquired obesity disorders rather than general physique or fat-loss use.

Now covers three indications

Beyond the original POMC/PCSK1/LEPR-deficiency and Bardet-Biedl syndrome indications, the FDA approved Imcivree in March 2026 for acquired hypothalamic obesity (age 4+) - hypothalamic damage, typically from a brain tumor or its treatment, that disrupts the same MC4R pathway. Unlike the genetic indications, this one does not require genetic testing.

Dosage Guidelines

Experience LevelDosage Range
Beginner0.5 – 1 mg/day
Intermediate2 – 3 mg/day
Frequency
Once-daily subcutaneous injection; individually titrated by the prescribing physician from a low starting dose up to a maintenance dose over roughly 2-4 weeks, per the FDA label.
Typical Cycle Length
52 – 52 weeks
Notes

Per the FDA label (DailyMed): for POMC/PCSK1/LEPR deficiency and Bardet-Biedl syndrome, patients aged 12+ start at 2mg/day for 2 weeks (ages 6 to under 12 start at 1mg/day; ages 2 to under 6 start around 0.5mg/day, weight-based), then increase toward a maintenance dose of up to 3mg/day - the approved ceiling for ages 6+ - if tolerated. For acquired hypothalamic obesity (age 4+), the starting dose is lower (0.5mg/day for 2 weeks) before a similar step-up. Steady state is reached within about 2 days, with roughly 30% accumulation over 12 weeks. This is prescription-only, physician-directed chronic therapy rather than a self-dosed "cycle" - the 52-week figure represents ongoing indefinite use, not a discrete run. Reference pricing at 2021 launch was about $330 per 1mg, so the ~3mg/day maintenance dose implies a roughly six-figure annual cost.

Side Effects

Skin Hyperpigmentation

very common
Severity
1.5/5

Darkening of the skin, an expected melanocortin effect (MC1R cross-activation) - the most common adverse reaction, reported in about 58% of patients vs 10% on placebo in the acquired-hypothalamic-obesity trial, and about 67% vs 0% during the 14-week placebo-controlled period of the Bardet-Biedl trial (FDA label).

Mitigation

Usually benign; discuss any concerning skin changes with the prescriber.

Injection Site Reactions

very common
Severity
1.5/5

Local reactions at the subcutaneous injection site - very common across trials (about 51% of treated patients in the Bardet-Biedl trial and up to 96% in the open-label POMC/PCSK1/LEPR studies); not reported as differentially more common than placebo in the acquired-hypothalamic-obesity trial specifically (FDA label).

Mitigation

Rotate injection sites.

Nausea / GI Effects

very common
Severity
1.5/5

Gastrointestinal effects including nausea (~55% vs 25% on placebo) and vomiting (~38% vs 19% on placebo) in the acquired-hypothalamic-obesity trial; diarrhea and abdominal pain are also very common (each reported in roughly a third of patients in the open-label POMC/PCSK1/LEPR studies), per the FDA label.

Mitigation

Usually manageable; report if persistent.

Headache

very common
Severity
1/5

One of the most common adverse reactions in trials, reported in about 37% of patients vs 31% on placebo in the acquired-hypothalamic-obesity trial (FDA label).

Mitigation

Usually mild and self-limited; report severe or persistent headache to the prescriber.

Spontaneous Penile Erections / Sexual Adverse Reactions

common
Severity
2/5

Spontaneous erections in males (~7% vs ~4% on placebo, FDA label) and adverse sexual reactions in females can occur, reflecting melanocortin (MC4R) activity.

Mitigation

Discuss with prescriber if problematic.

Depression / Suicidal Ideation

common
Severity
4/5

Depression and suicidal ideation are a listed Warning and Precaution (Section 5.2), not a rare event - in the open-label POMC/PCSK1/LEPR studies, depression was reported in about 26% of treated patients and suicidal ideation in about 11% (single-arm trials, no placebo comparator); depression is also named among the "most common adverse reactions" (incidence ≥20% in at least one trial population) across the label as a whole (FDA label).

Mitigation

Monitor mood closely throughout treatment; seek medical help for any new or worsening depression or suicidal thoughts, and discuss discontinuation with the prescriber if it occurs.

General Mitigation Strategies

Setmelanotide is a supervised prescription drug, so side-effect management is directed by the prescriber. Skin hyperpigmentation, injection-site reactions, GI effects and headache are very common (affecting roughly a third to the majority of patients) but generally mild. Depression/suicidal ideation is a genuine, actively-monitored risk (depression reported in roughly 1 in 4 patients and suicidal ideation in roughly 1 in 9 in the open-label genetic-obesity studies, not a rare event) - mood should be tracked throughout treatment. It is not androgenic and needs no PCT.

Post Cycle Therapy (PCT)

✓PCT Not Required

Not androgenic or anabolic. Does not affect the HPTA. No PCT required.

How It Works

Setmelanotide binds to and activates MC4 receptors in the paraventricular nucleus (PVN) of the hypothalamus and in the lateral hypothalamic area - a key node of the leptin-melanocortin pathway that regulates hunger and energy balance. Activation reduces appetite and increases resting energy expenditure, and does so without increasing heart rate or blood pressure. In the targeted disorders (POMC, PCSK1, LEPR deficiency, and BBS), this pathway is disrupted upstream of MC4R, and setmelanotide restores downstream MC4R signalling.

Fundamentals

Reference on the practices relevant to Setmelanotide: how they are done and where they go wrong. Not a recommendation to use it.

Reconstitution & concentration math→

Turning this powder into a measured dose

Sterile technique & injection-site infection→

Avoiding abscesses and cellulitis

Bloodwork: what to measure and when→

The markers that matter here

Warning signs & when to seek care→

When to stop and get help

WADA Status

✓Not Prohibited by WADA

Setmelanotide is a selective MC4R agonist with no established performance-enhancing or anabolic effect and is not specifically named on the WADA Prohibited List. As a prescription drug it would be used under medical supervision; athletes should still verify current status before competition.

References

Last updated: July 18, 2026